BioAlliance signs Oravig licensing contract with Vestiq
Pursuant to the agreement, BioAlliance will earn up to $44m from Vestiq, the initial $9m corresponding to unconditional payments to be spread over 24 months, and significant royalties
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
Proprietary modified-release CTAP101 capsules are designed to raise prohormone serum total 25-hydroxyvitamin D concentrations to targeted levels (at least 30 ng/mL), while avoiding upregulation of a cytochrome P-450